Identification and validation of new breast cancer biomarkers based on integrated metabolomics

Breast cancer is the most common cancer in women. It is therefore in the focus of approaches for the identification of predictive molecular biomarkers. In contrast to transcriptomics, the changes in metabolite levels that are associated with tumor development and progression have not been investigated to a great extent, so far. Metabolomics is defined as the study of all metabolites in a cell, tissue or organism, and the metabolome is regarded as the amplified output of a biological system.